Stock Analysis
- United States
- /
- Medical Equipment
- /
- NasdaqGM:HYPR
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results
Shareholders might have noticed that Hyperfine, Inc. (NASDAQ:HYPR) filed its third-quarter result this time last week. The early response was not positive, with shares down 8.3% to US$0.89 in the past week. Results were mixed, with revenues of US$3.6m beating expectations by 11%. Hyperfine continued to be lossmaking, reporting a US$0.14 statutory loss per share, in line with analyst forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
View our latest analysis for Hyperfine
Taking into account the latest results, the consensus forecast from Hyperfine's three analysts is for revenues of US$18.9m in 2025. This reflects a major 42% improvement in revenue compared to the last 12 months. The loss per share is expected to ameliorate slightly, reducing to US$0.55. Before this earnings announcement, the analysts had been modelling revenues of US$19.1m and losses of US$0.55 per share in 2025.
The consensus price target was unchanged at US$1.23, suggesting that the business - losses and all - is executing in line with estimates. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Hyperfine, with the most bullish analyst valuing it at US$1.50 and the most bearish at US$1.00 per share. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Hyperfine's past performance and to peers in the same industry. We would highlight that Hyperfine's revenue growth is expected to slow, with the forecast 33% annualised growth rate until the end of 2025 being well below the historical 58% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 8.2% annually. Even after the forecast slowdown in growth, it seems obvious that Hyperfine is also expected to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at US$1.23, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Hyperfine going out to 2026, and you can see them free on our platform here..
Before you take the next step you should know about the 2 warning signs for Hyperfine that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Hyperfine might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:HYPR
Hyperfine
A medical device company, provides magnetic resonance imaging (MRI) products in the United States.